Boyd Watterson Asset Management LLC OH lessened its holdings in Abbott Laboratories (NYSE:ABT) by 2.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,453 shares of the healthcare product maker’s stock after selling 945 shares during the quarter. Abbott Laboratories accounts for approximately 1.1% of Boyd Watterson Asset Management LLC OH’s investment portfolio, making the stock its 24th biggest position. Boyd Watterson Asset Management LLC OH’s holdings in Abbott Laboratories were worth $2,366,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in ABT. Tributary Capital Management LLC bought a new stake in Abbott Laboratories during the third quarter worth about $106,000. Heritage Trust Co lifted its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after purchasing an additional 200 shares during the period. Thompson Davis & CO. Inc. lifted its position in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after purchasing an additional 370 shares during the period. JFS Wealth Advisors LLC lifted its position in Abbott Laboratories by 349.0% during the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock worth $131,000 after purchasing an additional 2,094 shares during the period. Finally, Motco lifted its position in Abbott Laboratories by 213.7% during the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock worth $140,000 after purchasing an additional 1,962 shares during the period. 71.22% of the stock is owned by institutional investors.
In other news, insider Daniel Gesua Sive Salvadori sold 28,319 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $54.92, for a total value of $1,555,279.48. Following the completion of the transaction, the insider now owns 102,117 shares of the company’s stock, valued at $5,608,265.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Miles D. White sold 276,886 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the transaction, the chairman now directly owns 3,677,913 shares of the company’s stock, valued at approximately $200,115,246.33. The disclosure for this sale can be found here. In the last three months, insiders have sold 445,615 shares of company stock valued at $24,666,341. Insiders own 0.76% of the company’s stock.
Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $7.59 billion during the quarter, compared to the consensus estimate of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.65 earnings per share. sell-side analysts forecast that Abbott Laboratories will post 2.86 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.28 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $1.12 annualized dividend and a yield of 1.96%. Abbott Laboratories’s payout ratio is presently 560.00%.
Several equities research analysts recently weighed in on the stock. Wells Fargo & Co upped their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. William Blair raised shares of Abbott Laboratories from a “market perform” rating to an “outperform” rating in a research report on Thursday, January 25th. Jefferies Group reaffirmed a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, Morgan Stanley raised shares of Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price objective for the company in a research report on Tuesday, January 2nd. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $65.47.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2018/02/10/boyd-watterson-asset-management-llc-oh-sells-945-shares-of-abbott-laboratories-abt.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.